Tech-enabled DSUR literature review driven by biologit

Proven Results with biologit

At biologit, we are dedicated to supporting our clients with their pharmacovigilance needs. We recently supported a clinical biotech company by streamlining their DSUR literature review process to produce results in less than 5 days, and on budget. As a result of our cutting-edge platform and database, biologit was able to:

Review over 10,000 articles
Identify and remove 4,771 duplicates
Pinpoint 16 relevant safety articles

Recent Resources

Nicole Baker

10 min read

Case Study: Automated Literature Monitoring in Pharmacovigilance

A Compliance-Oriented Evaluation of Manual Versus AI-Driven Approaches a Scientific and Regulatory Perspective for Quality and Safety Professionals Abstract Medical literature monitoring is a core

Jean Redmond

4 min read

Biologit boosts patient safety with world-first automated local literature monitoring solution for non-indexed sources

Biologit, a specialist in advanced, technology-enabled safety surveillance solutions for life sciences, has launched a world-first automation solution for local literature monitoring. Biologit for Local

Sarah Jane Devaney

3 min read

Case Study: Comprehensive Data Sources for High Quality Literature Monitoring

Pharmacovigilance necessitates the comprehensive collection and analysis of data from diverse sources to evaluate pharmaceutical products effectively. Medical literature monitoring, in particular, is a pivotal

Nicole Baker

1 min read

Retrospective European Literature Search

Proven Results with biologit At biologit, we are committed to assisting our clients with their pharmacovigilance needs. Recently, we helped a biotech company conduct a

Naveen Basar

5 min read

Why Local Literature Matters in Pharmacovigilance

By Naveen Basar, Biologit Product Manager Literature Surveillance: An Essential Component of Pharmacovigilance In the world of pharmacovigilance, staying ahead of potential drug safety risk

Bruno Ohana

4 min read

FDA Compliant Literature Monitoring for Clinical Development

Small biotech and pharmaceutical companies in clinical development must understand and address safety risks in their compounds to ensure successful regulatory submissions. This requires the effective monitoring